HGSI will be merged by then with big pharma. Besides, patients responding to benlystsa will stay on benlysta. The virgin market would have been saturated with Benlysta by 2014. So newbies will have to look for new patients and Benlystsa failures. Who is to say will even pass the FDA muster. A lot can go worng during clinical trials.
Other new drugs for Lupus in the future will likely suffer a slow launch as well.....if they even make it to the approval process. Expect lots of volitionality, as these new drugs are a long way from approval.